First Bank & Trust Has $230,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)

First Bank & Trust decreased its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,624 shares of the company’s stock after selling 540 shares during the quarter. First Bank & Trust’s holdings in Castle Biosciences were worth $230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in CSTL. R Squared Ltd acquired a new position in shares of Castle Biosciences in the fourth quarter valued at approximately $42,000. Quest Partners LLC grew its position in shares of Castle Biosciences by 54.4% in the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after purchasing an additional 1,522 shares during the last quarter. US Bancorp DE grew its position in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after buying an additional 4,383 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Castle Biosciences during the third quarter worth approximately $140,000. Finally, Assetmark Inc. grew its position in Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after buying an additional 748 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insiders Place Their Bets

In other news, insider Derek J. Maetzold sold 9,364 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total value of $265,375.76. Following the completion of the transaction, the insider now directly owns 84,762 shares in the company, valued at approximately $2,402,155.08. This represents a 9.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders sold 30,771 shares of company stock worth $886,112 over the last three months. Insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. KeyCorp increased their price target on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Scotiabank increased their price target on Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group increased their price target on Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Lake Street Capital increased their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Stephens reissued an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $40.29.

Castle Biosciences Stock Down 3.8 %

NASDAQ CSTL opened at $26.15 on Friday. The business has a fifty day moving average price of $27.59 and a two-hundred day moving average price of $29.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. Castle Biosciences, Inc. has a fifty-two week low of $16.97 and a fifty-two week high of $35.84. The stock has a market capitalization of $732.46 million, a PE ratio of 130.76 and a beta of 0.91.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.